All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Diagnostics company Cytovale raised $84 million in Series C funding to commercialize its sepsis test, CEO Ajay Shah tells Axios.

Why it matters: Sepsis is the third-leading cause of death in U.S. hospitals.

Details: The round was led by Norwest Venture Partners with participation by new investors Sands Capital and Global Health Investment Corporation.

The financing included participation from other new and existing investors, as well as the conversion of bridge notes.

TD Cowen was Cytovale's financial adviser.

How it works: The San Francisco-based company's flagship product is an FDA-cleared rapid sepsis diagnosis test called IntelliSep.

IntelliSep assesses the body's immune response to an infection, using machine learning to characterize white blood cells' responses, which differ between septic and non-septic patients.

It generates a diagnostic result in under 10 minutes using standard blood draws.

What's next: Cytovale will use proceeds to bring IntelliSep to more hospital emergency departments and health systems around the country.

"This capital should give us runway for multiple years and puts us in a good position with this sizable round," Shah says.

The company is generating revenue but he declined to get into specifics.

What they're saying: "Sepsis is the number one cost of inpatient care in the U.S. and it kills more than breast cancer and opioids combined," says Shah.

"Until now, health care providers have lacked a fast and reliable test to inform treatment paths," says Norwest general partner Zack Scott.

"Offering the first early-detection test on the market, Cytovale has the incredible potential to dramatically improve how our healthcare system gets the right care to the right patients at the right time," says Scott.

Catch up fast: The company last raised in 2019, closing a $15 million Series B co-led by Breakout Ventures and Blackhorn Ventures.

Cytovale closes $84M Series C to market sepsis diagnostic

Cytovale gets $84M Series C to advance commercialization of rapid sepsis test.

Illustration of a stopwatch with a test tube instead of a second hand.

Health tech deals

Diagnostics company Cytovale raised $84 million in Series C funding to commercialize its sepsis test, CEO Ajay Shah tells Axios.Why it matters: Sepsis is the third-leading <a class="gtmContentClick" data-vars-link-text="cause of death" data-vars-click-url="https://link.axios.com/click/33377168.29/aHR0cHM6Ly93d3cuYWFtYy5vcmcvbmV3cy9zZXBzaXMtdGhpcmQtbGVhZGluZy1jYXVzZS1kZWF0aC11cy1ob3NwaXRhbHMtcXVpY2stYWN0aW9uLWNhbi1zYXZlLWxpdmVzP3V0bV9zb3VyY2U9bmV3c2xldHRlciZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj1zZW5kdG9fcHJvbmV3c2xldHRlcnRlc3Qmc3RyZWFtPXRvcA/63d7efa24889932dcb08ba1cBa79f5ff7" data-vars-content-id="0b129b22-8cfd-4624-b70f-8509ac5146e3" data-vars-headline="Cytovale closes $84M Series C to market sepsis diagnostic" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://link.axios.com/click/33377168.29/aHR0cHM6Ly93d3cuYWFtYy5vcmcvbmV3cy9zZXBzaXMtdGhpcmQtbGVhZGluZy1jYXVzZS1kZWF0aC11cy1ob3NwaXRhbHMtcXVpY2stYWN0aW9uLWNhbi1zYXZlLWxpdmVzP3V0bV9zb3VyY2U9bmV3c2xldHRlciZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj1zZW5kdG9fcHJvbmV3c2xldHRlcnRlc3Qmc3RyZWFtPXRvcA/63d7efa24889932dcb08ba1cBa79f5ff7" target="_self">cause of death</a> in U.S. hospitals.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

c-suite

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

Cytovale closes $84M Series C to market sepsis diagnostic

What to read next